Catherine Longworth is a reporter covering commercial and R&D developments in the medtech industry. A graduate of St. George's, University of London, Catherine holds a BSc in Biomedical Science. Before joining Informa, she worked in the editorial team at Pharmaceutical Press, the publishing division of the Royal Pharmaceutical Society, where she wrote and edited for a number of pharmaceutical publications. After gaining experience in the world of scientific publishing, Catherine took the leap to study a postgraduate qualification in journalism. During the course, she carried out placements with local London newspapers, writing general news and building her portfolio by reporting on a wide range of current affairs such as the European migrant crisis, political protests and the London mayoral election. Catherine is passionate about human rights and is fascinated by the innovative nature of the medtech industry and the healthcare advances that have the greatest benefit to mankind. She lives in London and loves music, arts, travel, writing, reading and is always happy to receive recommendations for books or places to travel!
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Catherine Longworth
Belgian start-up miDiagnostics has closed a €14m investment round to accelerate development of its silicon-chip-based diagnostics platform. The company believes the blood analyzer could deliver rapid test results in multiple settings.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
The UK government has ordered 3.5 million home test kits to identify people who have antibodies to the SARS-CoV-2 virus. However, it has not said who will supply the test kits.
Thermo Fisher has priced an offering of $2.2bn senior notes to pay for its planned acquisition of Qiagen. The news comes the same week, Qiagen confirmed Thierry Bernard as permanent CEO following the departure of former leader Peer Schatz.
Abbott has become the next major diagnostics company to receive an Emergency Use Authorization from the US FDA for a COVID-19 test.
Medtech Insight is tracking the IVD companies manufacturing tests for SARS-CoV-2, the coronavirus that causes COVID-19.